Shanghai Henlius
Founded Year
2009Stage
IPO | IPOTotal Raised
$381MDate of IPO
9/18/2019About Shanghai Henlius
Shanghai Henlius (02696.HK) is a joint venture company formed by Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals in December 2009. The company focuses on the development, production, and commercialization of mAb biosimilar drugs, bio-betters and mAbs. Products currently in development cover a variety of therapeutic areas including oncology and autoimmune diseases.
Missing: Shanghai Henlius's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Shanghai Henlius's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Shanghai Henlius
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Shanghai Henlius in 1 CB Insights research brief, most recently on Jan 11, 2023.
Expert Collections containing Shanghai Henlius
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Shanghai Henlius is included in 1 Expert Collection, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Shanghai Henlius Patents
Shanghai Henlius has filed 12 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immune system
- Immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/10/2019 | 3/15/2022 | Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Monoclonal antibodies for tumors | Grant |
Application Date | 4/10/2019 |
|---|---|
Grant Date | 3/15/2022 |
Title | |
Related Topics | Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Monoclonal antibodies for tumors |
Status | Grant |
Latest Shanghai Henlius News
Mar 3, 2023
Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase II drugs for Splenic Marginal Zone B-Cell Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rituximab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Rituximab biosimilar overview Rituximab (Hanlikangt, Rituximab Biosimilar) is a monoclonal antibody acts as an anti neoplastic agent. It is formulated as injectable solution for intravenous route of administration. Hanlikang is indicated for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, diffuse Large B-cell non-Hodgkin’s lymphoma, relapsed or refractory follicular lymphoma and it is in combination with methotrexate indicated for the treatment of moderately-to severely-active rheumatoid Arthritis (RA) in adult patients with who have inadequate response to one or more TNF-alpha antagonist therapies. Rituximab biosimilar (HLX-01) is under development idiopathic membranous nephropathy (iMN), follicular lymphoma, Extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or MALT-Lymphoma), splenic marginal zone B-cell lymphoma. The drug candidate is administered as intravenous injection. It was also under development for follicular lymphoma.
Shanghai Henlius Frequently Asked Questions (FAQ)
When was Shanghai Henlius founded?
Shanghai Henlius was founded in 2009.
Where is Shanghai Henlius's headquarters?
Shanghai Henlius's headquarters is located at Building B 1289 Yishan Road, Shanghai.
What is Shanghai Henlius's latest funding round?
Shanghai Henlius's latest funding round is IPO.
How much did Shanghai Henlius raise?
Shanghai Henlius raised a total of $381M.
Who are the investors of Shanghai Henlius?
Investors of Shanghai Henlius include Green Tomato, China International Capital Corporation, Xinhua Innovation Fund, Loyal Valley Capital, Fuguo Asset Management and 7 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.